OREANDA-NEWS. Criticism of the AstraZeneca coronavirus vaccine may have led the firm to focus on a different name, and the vaccine may now increasingly appear under the new name Vaxzevria. RIA Novosti was told about this by Philip Schmitt, founder of Cabinet Philippe Schmitt Avocats, a law firm specializing in industrial patents.

The EMA confirmed to RIA Novosti the change in the name of this vaccine on March 25, its website now has an entry "Vaxzevria (formerly AstraZeneca COVID-19 vaccine)". The agency noted that the company may change the name of its drug after its admission to the EU market. When she submits a request for such a change, the EMA only assesses whether the new name could create certain problems to prevent confusion errors.

Earlier, the EMA announced that it is investigating incidents with patients who received the vaccine from the same batch of AstraZeneca vaccine in several EU countries and who later had thromboembolic complications. Several European countries have suspended the use of the AstraZeneca vaccine. The EMA later made a recommendation to continue using the drug.

At a certain stage, the company chooses one or more brands for its drugs. According to Schmitt, often the same medicine or vaccine has more than one name depending on the region of the world.

The expert concluded that criticism of the effectiveness or uneven supply of AstraZeneca / Oxford did not promote the brand's advertising. He believes that “therefore the firm seems to now prefer to underline the link to its product rather than the company name. And we are likely to see links to Vaxzevria more and more, as EMA is starting to do, no doubt , at the request of AstraZeneca ".